TrialThe Lancet. Oncology2013

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

John Farley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.